Everest Medicines Acquires Etripamil Rights from Corxel – USD 50 Million Deal for First‑in‑Class PSVT Nasal Spray in Greater China
Everest Medicines Limited (HKG: 1952) has entered into an asset acquisition agreement with Corxel Pharmaceuticals...
HKG: 1952
Everest Medicines Signs LOI to Acquire Haisen Pharmaceutical – RMB 200 Million Deposit for 14‑Product APAC Commercial Platform
Everest Medicines Limited (HKG: 1952) announced the signing of a letter of intent to acquire...
Everest Medicines Reports Positive Phase IIa Data for VIS-101 – Dual VEGF-A/Ang-2 Inhibitor Shows Best-in-Class Potential in wAMD
Everest Medicines (HKG: 1952) announced positive topline results from its Phase IIa study of VIS-101,...
Everest Medicines Launches Etrasimod in China – Next-Gen S1P Modulator Hits Market for Ulcerative Colitis
Everest Medicines (HKG: 1952) announced the formal commercial launch of Etrasimod, with the first prescription...
Everest Medicines Files Velsipity for Ulcerative Colitis in China
Everest Medicines (HKG: 1952) announced it has submitted a marketing filing in China for Velsipity...
Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal
Everest Medicines Limited (HKG: 1952) announced a licensing agreement with Micot, a polypeptide NME drug...
Everest lerodalcibep PCSK9 FDA Approval Targets China Launch
Everest Medicines Limited (HKG: 1952) announced that the U.S. FDA has approved the Biologics License...
Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal
Hasten Biopharmaceutical Co., Ltd. and Everest Medicines Limited (HKG: 1952) announced two strategic agreements: a...
Everest Medicines Secures Exclusive Rights to VIS‑101 in Greater China, Potential 2026 Phase 3 Launch
Hong Kong‑listed Everest Medicines Limited (HKG: 1952) today announced a strategic agreement with Visara, Inc.,...
I‑Mab Announces Global Transformation, NovaBridge Rebranding, and $37 M Acquisition of VIS‑101
I‑MAB Biopharma (NASDAQ: IMAB), a public company under the CBC Group, today revealed a strategic...
Everest Medicines Commences Global Phase I Trial of Universal mRNA Cancer Vaccine EVM14
Everest Medicines Limited (HKG: 1952) announced today that the first patient has been successfully dosed...
Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14
Everest Medicines Limited (HKG: 1952) announced today that the National Medical Products Administration (NMPA) has...
Everest Medicines Reports 48 % YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone
Everest Medicines Limited (HKG: 1952) released unaudited interim financial results for the six months ended...
Everest Medicines’ Velsipity NDA Accepted for Review in Taiwan
China-based Everest Medicines (HKG: 1952) announced that the New Drug Application (NDA) for its Velsipity...
Everest Medicines’ Nefecon Granted Full Approval by Taiwan’s TFDA for IgA Nephropathy
China-based Everest Medicines (HKG: 1952) announced today that the Taiwan Food and Drug Administration (TFDA)...
Everest Medicines Completes HK$1.57 Billion Share Placement to Advance R&D and Commercialization
China-based Everest Medicines (HKG: 1952) announced today the completion of a share placement of 22,561,000...
Everest Medicines’ Nefecon Receives Full Approval from NMPA for IgAN Treatment
China-based Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has converted...
Everest Medicines Reports Surge in Revenue, Advances Core Products and R&D Pipeline
China-based Everest Medicines (HKG: 1952) has announced its 2024 financial results, marking a significant milestone...
Everest Medicines’ EVM14 mRNA Cancer Vaccine Clears US FDA IND Application
China-based Everest Medicines (HKG: 1952) has announced that its Investigational New Drug (IND) application for...
Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production
China-based Everest Medicines (HKG: 1952) announced the start of construction for a manufacturing plant in...